Live Marvell Technology Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Entrada Therapeutics, Inc.

Get SEC filing alerts via email and in your feed for Entrada Therapeutics, Inc.

TRDA

Entrada Therapeutics, Inc.

About Entrada Therapeutics, Inc.

Entrada Therapeutics, Inc. is a biopharmaceutical company focused on developing intracellular therapeutics using its proprietary Endosomal Escape Vehicle (EEV) platform. The company advances treatments for rare neuromuscular diseases, genetic disorders, and ocular conditions by enabling targeted delivery of nucleic acids, proteins, and other molecules into cells. Its portfolio includes clinical-stage candidates for Duchenne muscular dystrophy, myotonic dystrophy, and other diseases, leveraging innovative delivery technologies to address unmet medical needs.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from Entrada Therapeutics, Inc.

1
1
Entrada Therapeutics, Inc. Entrada Therapeutics Reports 95% Decline in Collaboration Revenue and Increased Net Losses in Q1 2026

Via official filing (AI summary) | 29 days ago | 0 comments

2
1
Entrada Therapeutics, Inc. Entrada Therapeutics Reports $25.4M Collaboration Revenue and $143.8M Net Loss for 2025

Via official filing (AI summary) | 3 months ago | 0 comments

3
1
Entrada Therapeutics, Inc. Entrada Therapeutics Reports $44.1 Million Net Loss and Declining Collaboration Revenue in Latest Quarter

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
Entrada Therapeutics, Inc. Entrada Therapeutics Reports Significant Revenue Decline and Increased Net Loss in Q2 2025

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
Entrada Therapeutics, Inc. Entrada Therapeutics Reports Significant Decline in Q1 2025 Financial Performance

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
Entrada Therapeutics, Inc. Entrada Therapeutics Reports Significant Financial Growth, Net Loss Improvement in Q3 2024

Via official filing (AI summary) | over 1 year ago | 0 comments